Clinical Trial Detail

NCT ID NCT02296801
Title A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer
Recruitment Active, not recruiting
Gender female
Phase Phase II
Variant Requirements yes
Sponsors NSABP Foundation Inc
Indications

Her2-receptor negative breast cancer

Therapies

Palbociclib

Letrozole

Age Groups: adult

Additional content available in CKB BOOST